The Female Reproductive Hormones
A complete account of the hormones governing female reproductive physiology — from GnRH, FSH, and LH through oestrogen and progesterone, inhibin, AMH, prolactin, and oxytocin; the HPG axis; the menstrual cycle; ovulation; pregnancy; the menopausal transition; and how these hormones underpin contraception, fertility treatment, and HRT.
Female reproductive physiology is one of the most coordinated and continuously regulated biological systems in the human body. Every month throughout the reproductive years, a precisely timed sequence of hormonal signals initiates follicle growth, selects a dominant follicle, triggers ovulation, prepares the uterus for potential implantation, and either sustains an early pregnancy or dismantles the preparation and begins again. This entire programme — spanning roughly 28 days on average, repeating approximately 400 times in a woman’s lifetime — is choreographed by a small ensemble of hormones whose concentrations, timing, and interactions determine whether conception occurs, whether pregnancy is maintained, and how the transition to menopause unfolds. Understanding these hormones is not an abstract exercise in biochemistry: it is the foundation of obstetrics and gynaecology, reproductive medicine, contraception, and the clinical management of conditions affecting millions of women worldwide.
The Hypothalamic-Pituitary-Gonadal Axis — The Hormonal Command Hierarchy
Female reproductive endocrinology is organised as a three-tier hierarchy — the hypothalamic-pituitary-gonadal (HPG) axis — in which hormonal signals flow downward from the hypothalamus to the anterior pituitary to the ovaries, and feedback signals flow upward from the ovaries to regulate the upper tiers. This hierarchical architecture allows a single central structure (the hypothalamus) to coordinate reproductive function with the broader physiological state: energy availability, stress, circadian rhythm, and season all influence hypothalamic GnRH secretion, allowing the reproductive system to respond appropriately when conditions are favourable and to suppress itself when they are not.
Tier 1 — Hypothalamus: GnRH Pulse Generator
The hypothalamus contains specialised GnRH-secreting neurons — approximately 1,000–2,000 cells concentrated in the arcuate nucleus and preoptic area — that fire in coordinated pulses every 60–120 minutes, releasing GnRH (gonadotrophin-releasing hormone, also called LHRH) in discrete boluses into the hypothalamo-pituitary portal vasculature. This pulsatile pattern is critical: continuous GnRH exposure paradoxically suppresses pituitary gonadotrophin secretion (the basis of GnRH agonist therapy), while pulsatile GnRH stimulates it. The GnRH pulse generator is regulated by two key neuronal populations: kisspeptin neurons (stimulatory) and neurokinin B / dynorphin neurons (inhibitory), whose balance determines pulse frequency and amplitude. Metabolic signals (leptin, ghrelin, insulin), stress hormones (cortisol, CRH), and opioids all modulate kisspeptin neuronal activity — providing the mechanistic link between energy balance, psychological stress, and reproductive function.
Tier 2 — Anterior Pituitary: Gonadotroph Cells
GnRH binds to GnRH receptors (GPCRs) on gonadotroph cells in the anterior pituitary, stimulating synthesis and secretion of two glycoprotein hormones: FSH (follicle-stimulating hormone) and LH (luteinising hormone). Both share a common alpha subunit (also shared with TSH and hCG) and differ in their specific beta subunits, which determine receptor specificity. FSH and LH secretion is not identical — the ratio of FSH to LH secreted in response to GnRH depends on GnRH pulse frequency (slow pulses favour FSH; fast pulses favour LH), gonadal steroid feedback, and inhibin levels. The mid-cycle LH surge — the hormonal trigger for ovulation — reflects the remarkable amplification of GnRH-stimulated LH release when oestrogen feedback switches from negative to positive, driving LH secretion to 5–10 times its baseline level within 24–36 hours.
Tier 3 — Ovaries: Steroid and Peptide Hormone Production
The ovaries respond to FSH and LH with follicle development and hormone synthesis. FSH drives granulosa cell proliferation and aromatase expression, converting androgens (supplied by LH-stimulated theca cells) to oestradiol — the two-cell, two-gonadotrophin model of ovarian steroidogenesis. As the dominant follicle matures, it produces rising quantities of oestradiol and inhibin B. After ovulation, the ruptured follicle transforms into the corpus luteum, which produces large amounts of progesterone and oestradiol under LH stimulation. The ovaries also produce AMH from small follicles, and a range of local growth factors (IGF-1, EGF, activin) that modulate follicle development independent of pituitary signals.
Feedback Loops — Negative and Positive
Ovarian hormones regulate the hypothalamic and pituitary tiers through two distinct feedback mechanisms. Negative feedback (operating throughout most of the cycle) means rising oestradiol, progesterone, and inhibin suppress GnRH, FSH, and LH — preventing runaway stimulation and regulating cycle length. Positive feedback (operating only at mid-cycle, when oestradiol exceeds approximately 200 pg/mL for more than 50 hours) means rising oestradiol briefly amplifies GnRH pulse frequency and sensitises gonadotrophs to GnRH, triggering the LH surge and ovulation. This switch from negative to positive oestrogen feedback is unique among feedback systems — its molecular basis involves oestrogen receptor alpha signalling in kisspeptin neurons — and its failure (as in polycystic ovary syndrome, hypothalamic amenorrhoea, or premature ovarian insufficiency) prevents ovulation and causes infertility.
GnRH — Structure, Pulsatility, and Pharmacological Targeting
Gonadotrophin-releasing hormone (GnRH) is a decapeptide (ten amino acid) hormone, synthesised in the hypothalamus and delivered to the anterior pituitary via the hypothalamo-pituitary portal blood system — a short vascular link that allows very high local concentrations to reach pituitary gonadotrophs without significant dilution in the systemic circulation. The amino acid sequence of GnRH (pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂) has been completely conserved across vertebrate species, reflecting the evolutionary antiquity and indispensability of this signal.
Why Pulsatility Is Non-Negotiable
The pulsatile requirement for GnRH action is one of the most important principles in reproductive endocrinology. When GnRH is delivered continuously rather than in pulses, GnRH receptors on pituitary gonadotrophs become desensitised and downregulated within hours — FSH and LH secretion falls dramatically, and within weeks gonadal steroid production is suppressed to castrate levels. This paradoxical effect of continuous GnRH is the foundation of GnRH agonist therapy: drugs like leuprorelin, goserelin, and buserelin — which are GnRH analogues with longer half-lives than native GnRH — initially cause a brief “flare” of FSH and LH release, followed by sustained gonadotrophin suppression within 2–4 weeks. This pharmacological castration is used in prostate cancer, endometriosis, uterine fibroids, central precocious puberty, and as part of ovarian stimulation protocols in IVF cycles.
GnRH Antagonists — Immediate Suppression
GnRH antagonists (cetrorelix, ganirelix) bind GnRH receptors competitively and block GnRH action without the initial flare — producing immediate, dose-dependent gonadotrophin suppression within hours of the first dose. This avoids the flare response of GnRH agonists, which can be problematic in oestrogen-sensitive conditions (endometriosis flare, ovarian cyst stimulation). In assisted reproduction, GnRH antagonist protocols are increasingly used alongside FSH ovarian stimulation to prevent premature LH surges — allowing flexible timing of hCG trigger and reducing the risk of ovarian hyperstimulation syndrome. Oral GnRH antagonists (elagolix, relugolix, linzagolix) now approved for endometriosis and uterine fibroids have transformed the management of these conditions by providing reversible medical suppression without injection.
FSH and LH — The Pituitary Gonadotrophins That Drive the Ovarian Cycle
Follicle-stimulating hormone and luteinising hormone are the pituitary’s direct messengers to the ovary. Both are glycoproteins — proteins with complex carbohydrate (oligosaccharide) chains attached post-translationally that are critical for their biological activity, half-life, and receptor binding. Their shared alpha subunit (alpha-FSH/LH) is encoded by the same gene as the alpha subunit of TSH and hCG, explaining why hCG can cross-react in LH assays and why hCG — with a much longer half-life — can substitute for LH in clinical protocols.
Oestradiol synthesis in the ovary requires two distinct cell types and both FSH and LH — a key concept for understanding ovarian physiology and the pharmacology of ovarian stimulation. Theca cells (regulated by LH) express LH receptors and the steroidogenic enzymes CYP17A1 and CYP11A1, producing androstenedione and testosterone from cholesterol — but lack significant aromatase activity. Granulosa cells (regulated by FSH) express FSH receptors and high levels of aromatase (CYP19A1), converting theca-derived androgens to oestradiol — but cannot synthesise androgens de novo (lacking CYP17A1). Thus, LH drives androgen substrate production in theca cells; FSH drives aromatisation in granulosa cells. The dominant follicle becomes the oestradiol-producing unit because it has the highest aromatase activity and the most granulosa cells; atretic follicles accumulate androgens but cannot convert them, creating an androgenic intrafollicular microenvironment that promotes further atresia.
For students working on reproductive endocrinology assignments, this model appears consistently in examination questions and assessment criteria. Our nursing assignment help, biology assignment help, and public health assignment help cover reproductive physiology at all academic levels.
Oestrogen — Synthesis, Receptor Subtypes, and Physiological Actions
Oestrogen is not a single hormone but a family of structurally related steroid hormones that share a phenolic A-ring — the structural feature that distinguishes oestrogens from other steroid classes and confers high affinity for oestrogen receptors. The three endogenous oestrogens are oestradiol (E2), oestrone (E1), and oestriol (E3), differing in the number of hydroxyl groups on their steroid ring structure and consequently in their potency and principal physiological context.
The Dominant Reproductive-Age Oestrogen
Oestradiol is the most potent endogenous oestrogen — approximately 80 times more potent than oestrone at the oestrogen receptor. In reproductive-age women, it is produced primarily by granulosa cells of developing ovarian follicles and the corpus luteum, with smaller contributions from peripheral aromatisation of androstenedione in adipose tissue, skin, and muscle. Oestradiol concentrations vary dramatically across the menstrual cycle: 20–150 pg/mL in the early follicular phase, rising to 150–750 pg/mL at the pre-ovulatory peak, then declining and stabilising at 40–250 pg/mL in the luteal phase. After menopause, circulating oestradiol typically falls below 20 pg/mL, with oestrone becoming the dominant circulating oestrogen through peripheral aromatisation.
The Post-Menopausal Dominant Oestrogen
Oestrone is a weaker oestrogen (approximately 1/10th the potency of oestradiol at the receptor), produced predominantly by peripheral aromatisation of androstenedione (of adrenal origin) in adipose tissue, liver, skin, and muscle. It is the dominant circulating oestrogen after menopause, and its concentration — unlike oestradiol — correlates with adipose tissue mass, explaining why obesity provides partial protection against post-menopausal osteoporosis (through higher peripheral oestrone production) but simultaneously increases breast and endometrial cancer risk (through the same mechanism). Oestrone and oestradiol are interconvertible by 17-beta-hydroxysteroid dehydrogenase; the oestrone:oestradiol ratio in peripheral tissues determines local oestrogenic activity.
The Pregnancy Oestrogen
Oestriol is the weakest of the three principal oestrogens, produced in enormous quantities by the fetoplacental unit during pregnancy — the foetal liver and adrenal glands provide sulphated precursors (DHEAS) that the placenta converts to oestriol via the enzyme 17-beta-hydroxysteroid dehydrogenase and placental sulfatase. Unconjugated oestriol in maternal serum is a component of the second-trimester quadruple test for Down syndrome screening — low oestriol (combined with high AFP and high hCG in Down syndrome) is part of the risk calculation. Outside pregnancy, oestriol is used in some vaginal formulations for urogenital atrophy because its weak systemic absorption and short half-life produce local oestrogenic effects with minimal systemic endometrial stimulation.
ERα, ERβ, and GPER
Oestrogen acts through three receptor subtypes with different tissue distributions and downstream effects. Oestrogen receptor alpha (ERα, ESR1) predominates in the uterus, breast, hypothalamus, pituitary, bone (osteoblasts), liver, and adipose tissue — mediating most classical reproductive oestrogenic effects. ERβ (ESR2) predominates in ovarian granulosa cells, lung, brain, intestine, and immune cells — often opposing or modulating ERα activity. Both ERα and ERβ are nuclear receptors — upon oestrogen binding, they dimerize, translocate to the nucleus, and bind oestrogen response elements (EREs) to regulate gene transcription. GPER (G-protein-coupled oestrogen receptor, formerly GPR30) mediates rapid non-genomic oestrogenic effects at the cell membrane — activating second-messenger cascades within seconds to minutes, independent of gene transcription. Selective ERα vs. ERβ activity profiles explain why drugs like tamoxifen (ERα antagonist in breast, agonist in bone) and raloxifene can produce tissue-selective oestrogenic effects.
Uterus, Cervix, Vagina, Fallopian Tubes
In the uterus, oestradiol drives endometrial proliferation — stimulating glandular and stromal cell division, increasing blood vessel growth, and preparing the endometrium for the secretory transformation driven by progesterone in the luteal phase. In the cervix, oestrogen thins and hydrates cervical mucus, producing the characteristic “spinnbarkeit” (stretchiness) and ferning pattern of mid-cycle mucus that facilitates sperm penetration. In the vagina, oestrogen stimulates glycogen deposition in epithelial cells (substrate for lactobacilli, maintaining acidic pH), epithelial proliferation, and mucosal lubrication. In the fallopian tubes, oestrogen increases ciliary beat frequency and smooth muscle contractility, facilitating oocyte and embryo transport.
Bone, Brain, Cardiovascular, Metabolic
Oestrogen’s actions extend far beyond reproduction. In bone, ERα-mediated signalling in osteoblasts increases bone formation and suppresses osteoclast activity — explaining why oestrogen withdrawal at menopause accelerates bone resorption and causes osteoporosis. In the cardiovascular system, oestrogen promotes nitric oxide synthesis (vasodilation), improves endothelial function, and modulates lipid metabolism (increasing HDL, decreasing LDL). In the brain, oestrogen affects serotonin and dopamine neurotransmission, influences mood and cognition, and modulates thermoregulation — explaining hot flushes when oestrogen falls abruptly. In the liver, oestrogen regulates coagulation factor synthesis, SHBG production, and IGF-1 release — effects that are amplified with oral compared to transdermal oestrogen because oral administration subjects the first-pass hepatic metabolism to high portal oestrogen concentrations.
Progesterone — The Luteal Phase Hormone and Pregnancy Sustainer
Progesterone (from the Latin pro gestare — in favour of gestation) is a 21-carbon steroid hormone, structurally identical in male and female physiology but produced in reproductive quantities only from specific female tissues: the corpus luteum (primary source in the non-pregnant cycle), the placenta (dominant source from approximately 10 weeks of pregnancy), and the adrenal cortex (minor background contribution). Like oestrogen, progesterone is synthesised from cholesterol via pregnenolone, and acts primarily through nuclear receptors (progesterone receptor A and B isoforms — PR-A, PR-B) to regulate gene transcription, with additional rapid non-genomic effects through membrane-associated progesterone receptors.
Endometrium — Secretory Transformation
Progesterone converts the oestrogen-primed proliferative endometrium to a secretory endometrium: glands become tortuous and glycogen-rich, stroma becomes oedematous, and spiral arteries develop — creating a receptive environment for blastocyst implantation. This “implantation window” (days 20–24 of a 28-day cycle) is the only period when the endometrium can accept an embryo. Progesterone simultaneously suppresses endometrial oestrogen receptor expression — limiting further proliferative stimulation — and upregulates 17-beta-HSD activity, converting local oestradiol to less potent oestrone.
Cervix and BBT — Secondary Contraceptive Effects
Progesterone thickens cervical mucus to a viscous, cellular-rich consistency that is impenetrable to sperm — the opposite of the thin, acellular, sperm-permissive mid-cycle mucus produced under oestrogen influence. This is the primary mechanism of progestogen-only contraception at the cervix. Progesterone also raises basal body temperature (BBT) by 0.2–0.5°C through a direct thermogenic effect on the hypothalamus — the basis of BBT charting for fertility awareness and retrospective confirmation of ovulation in clinical assessment.
Uterus in Pregnancy — Myometrial Quiescence
Progesterone relaxes the myometrium by reducing gap junction formation between smooth muscle cells, suppressing oxytocin receptor expression, and modulating prostaglandin synthesis — maintaining uterine quiescence throughout pregnancy. The dramatic fall in progesterone (or shift in progesterone receptor isoform balance towards a dominant PR-A repressor form) in late pregnancy contributes to the withdrawal of myometrial inhibition that allows labour to begin. Progesterone supplementation (vaginal progesterone, 17-hydroxyprogesterone caproate) is used clinically to reduce preterm birth risk in women with short cervix or prior preterm delivery.
MENSTRUAL CYCLE: Follicular phase: <1–3 nmol/L Low — no corpus luteum Ovulation: ~3–15 nmol/L Beginning to rise post-LH surge Mid-luteal peak: 16–95 nmol/L Peak day 21 in 28-day cycle Late luteal: Falls to <5 Corpus luteum regression → menstruation CLINICAL CUTOFFS: Day 21 progesterone >30 nmol/L → Ovulation confirmed (UK laboratory standard) Day 21 progesterone <16 nmol/L → Likely anovulatory cycle Day 21 progesterone 16–30 nmol/L→ Borderline — consider repeat or earlier peak PREGNANCY: First trimester (corpus luteum): 25–90 nmol/L Rising under hCG stimulation Second trimester (placental): 100–500 nmol/L Dominant placental production Third trimester: 300–700 nmol/L Maintains myometrial quiescence CLINICAL NOTE: Day 21 assumes a 28-day cycle — in longer cycles, sampling should be adjusted to 7 days before the expected next period (e.g., day 28 in a 35-day cycle) to capture the mid-luteal peak accurately.
The progesterone receptor exists in two major isoforms — PR-A and PR-B — encoded by the same gene but with different N-terminal domains. PR-B is the primary transcriptional activator in most tissues; PR-A often acts as a repressor of PR-B (and ERα) activity when expressed at higher levels. The ratio of PR-A to PR-B changes in target tissues across the menstrual cycle and in pathological states: endometriosis shows abnormal PR-A dominance contributing to progesterone resistance, and PR-A upregulation in late pregnancy myometrium is a key component of the functional progesterone withdrawal that initiates parturition without requiring a fall in circulating progesterone. Understanding this isoform biology is relevant to explaining why progesterone supplementation works in some clinical contexts (luteal phase support in IVF) but has limited efficacy in others (threatened miscarriage when PR-A resistance is already established).
Inhibin and AMH — The Ovarian Reserve Signal Hormones
Beyond oestrogen and progesterone, the ovary produces several additional hormones that communicate the state of the follicle pool to the pituitary and systemic circulation. Inhibin B, inhibin A, and anti-Müllerian hormone (AMH) each provide distinct information about different compartments of the ovarian follicle hierarchy, and together they form the basis of clinical ovarian reserve assessment.
Inhibin B — Follicular Phase Marker
Inhibin B is a dimeric glycoprotein (inhibin B alpha + beta-B subunit) produced by granulosa cells of small antral follicles (2–10 mm) under FSH stimulation. Its primary action is specific suppression of FSH secretion from the anterior pituitary — the “inhibin” action — without affecting LH. Inhibin B peaks in the early-to-mid follicular phase, reflecting the cohort of FSH-responsive follicles. In perimenopausal women, declining inhibin B — reflecting shrinking follicle numbers — is the earliest hormonal change, preceding the rise in FSH and the fall in oestradiol. Low inhibin B on cycle day 3 was historically used as an ovarian reserve marker, now largely supplanted by AMH.
Inhibin A — Luteal Phase Dominant
Inhibin A (alpha + beta-A subunit) is produced primarily by the dominant follicle and corpus luteum, peaking in the mid-luteal phase. It similarly suppresses FSH from the pituitary. During the luteal phase, the combination of oestradiol, progesterone, and inhibin A maintains FSH suppression — preventing new follicle recruitment while the corpus luteum is functioning. At the end of the luteal phase, when corpus luteum regresses and inhibin A falls alongside progesterone and oestradiol, FSH rises again to initiate the next follicular wave. In pregnancy, inhibin A is produced by the placenta and is a component of the second-trimester Down syndrome screening quadruple test (elevated in affected pregnancies).
AMH — Ovarian Reserve Quantifier
Anti-Müllerian hormone (AMH), produced by granulosa cells of pre-antral and small antral follicles (1–8 mm), reflects the size of the primordial follicle pool — the total reserve of eggs remaining. AMH is stable across the menstrual cycle (unlike FSH and oestradiol), does not require cycle-timed sampling, declines steadily from the mid-20s, and becomes undetectable around menopause. Clinically: AMH predicts ovarian response to stimulation in IVF; diagnoses premature ovarian insufficiency; monitors ovarian function after chemotherapy; and is elevated in PCOS (large pool of small antral follicles). Reference ranges: peak reproductive years: 14–48 pmol/L; low reserve: <5.4 pmol/L; undetectable (<2 pmol/L): consistent with menopause.
The Menstrual Cycle — A Phase-by-Phase Hormonal Analysis
The menstrual cycle is the monthly recurrence of follicle development, ovulation, corpus luteum formation, and — in the absence of conception — luteal regression and menstruation, all coordinated by the sequential and interacting hormonal signals of the HPG axis. A standard 28-day cycle is divided into the follicular phase (days 1–13), ovulation (day 14), and the luteal phase (days 15–28), though cycle length varies from 21 to 35 days in healthy women, with almost all of this variation in the length of the follicular phase — the luteal phase duration is remarkably constant at 12–14 days across individuals and cycles.
Days 1–4: Menstruation and FSH Rise
Menstruation begins with the progesterone and oestrogen withdrawal that follows corpus luteum regression — triggering endometrial ischaemia (spiral artery vasoconstriction), prostaglandin-driven myometrial contractions, and shedding of the functional endometrial layer. Simultaneously, the loss of inhibin A, oestradiol, and progesterone negative feedback allows FSH to rise — reaching its early cycle peak around day 3–5. This FSH rise recruits a cohort of 5–15 antral follicles (2–5 mm) from the pool of growing follicles that have been maturing independently over the preceding 60–70 days (the follicle development timeline extends well before the cycle in which selection occurs).
Days 5–9: Follicle Recruitment and Selection
Under FSH stimulation, the cohort of recruited follicles begins growing — granulosa cells proliferate, the follicular antrum (fluid-filled cavity) forms, and oestradiol production rises progressively. As oestradiol rises, negative feedback progressively reduces FSH secretion. Follicles differ in their FSH sensitivity — determined by FSH receptor number, local IGF-1 levels, and growth factor microenvironment. As FSH falls, follicles with lower FSH sensitivity cannot maintain growth and undergo atresia; the one or two follicles with highest FSH sensitivity continue growing despite lower FSH levels. This selection process — by which a single dominant follicle (DF) emerges while all others undergo atresia — is the mechanism by which monoovulation is normally maintained. The emerging DF is typically 10 mm by day 8–9 and shows the most robust FSH signalling and oestradiol production.
Days 10–12: Dominant Follicle Growth and Oestradiol Peak
The dominant follicle grows at approximately 2 mm per day, reaching 18–24 mm at maturity. Its granulosa cell mass expands markedly, producing a steep rise in oestradiol — reaching 200–750 pg/mL in the 2–3 days before ovulation. This peak oestradiol concentration, sustained for more than 50 hours, is the signal that switches pituitary oestrogen feedback from negative to positive — activating the oestrogen-positive feedback mechanism. The cervical mucus becomes progressively thinner, clearer, more abundant, and more elastic under oestrogen influence — the peak of mucus quality at mid-cycle (Billings Method observable) coincides with maximum fertility. The endometrium, under continuous oestradiol stimulation, reaches 8–14 mm triple-line appearance on ultrasound by the late follicular phase.
Day 14: The LH Surge and Ovulation
The sustained high oestradiol level from the dominant follicle triggers a GnRH pulse frequency acceleration, which drives a massive, sudden release of LH from pituitary gonadotrophs — the LH surge. LH levels rise 5–10-fold within 12–24 hours, peak, and then decline over the following 24 hours. Within the dominant follicle, the LH surge triggers resumption of meiosis I in the oocyte (arrested since foetal life), activates prostaglandin synthesis causing smooth muscle contraction and proteolytic enzyme release that digest the follicle wall, and initiates luteinisation of granulosa cells — beginning progesterone production. Follicle rupture — expelling the mature oocyte and cumulus complex into the peritoneal cavity to be captured by the fallopian tube fimbriae — occurs approximately 36 hours after the LH surge peak.
Days 15–25: The Luteal Phase — Corpus Luteum Function
After follicle rupture, the collapsed follicle is vascularised and transformed — granulosa and theca cells luteinise, becoming the corpus luteum. This highly vascular glandular structure secretes large quantities of progesterone (16–95 nmol/L at mid-luteal peak) and oestradiol under LH stimulation, transforming the endometrium to its secretory configuration and creating the implantation window. The corpus luteum has a finite lifespan of 12–14 days in the absence of pregnancy — after which it undergoes luteolysis (regression), driven by local prostaglandin production and declining LH pulsatility. Progesterone, oestradiol, and inhibin A all fall as the corpus luteum regresses. If conception and implantation occur, hCG from the trophoblast reaches the corpus luteum within days and rescues it from luteolysis — the luteal-placental shift that maintains the pregnancy until the placenta can produce sufficient progesterone autonomously (approximately weeks 8–10).
Days 26–28: Luteal Regression and Premenstrual Phase
Corpus luteum regression produces the hormonal withdrawal — falling progesterone and oestradiol — that drives the premenstrual and menstrual transitions. Progesterone withdrawal from a sensitised endometrium triggers prostaglandin release, endometrial ischaemia, and the inflammatory cascade that produces menstruation. FSH begins to rise as negative feedback is removed, initiating the next follicular cohort. The premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) occur in the late luteal phase when progesterone (and its neuroactive metabolite allopregnanolone) is still elevated, likely reflecting abnormal central nervous system sensitivity to normal luteal phase hormonal changes rather than abnormal hormone levels per se.
Ovulation in Detail — The Biological Event That Defines Fertility
Ovulation is the central event of the female reproductive cycle — the release of a mature, fertilisable oocyte from the dominant follicle into the peritoneal cavity. It is simultaneously the culmination of a month-long hormonal preparation, the trigger for the luteal phase hormonal shift, and the only moment in the cycle when conception is biologically possible. Understanding ovulation at the cellular and molecular level is essential for clinical management of anovulatory infertility, ovulation induction, and assisted conception.
LH Surge to Follicle Rupture
The interval between the LH surge peak and ovulation — used to time hCG trigger injections (which mimic the LH surge) and intrauterine insemination procedures in fertility treatment
Fertile Lifespan of the Oocyte
The window during which the ovulated oocyte can be fertilised — shorter than the 3–5 day fertile lifespan of sperm, making sperm present at ovulation more critical than intercourse immediately after ovulation
Dominant Follicle Diameter at Ovulation
The follicle size range at which ovulation typically occurs — monitored by transvaginal ultrasound during ovulation induction and IVF cycles to time trigger and oocyte retrieval
The molecular events within the dominant follicle during the LH surge are highly orchestrated. LH receptor activation increases intraovarian progesterone production — which, combined with local prostaglandins (primarily PGE2, synthesised via COX-2 upregulated by LH), drives the inflammatory cascade required for follicle rupture. Matrix metalloproteinases (MMPs) digest the follicle wall basement membrane and surrounding connective tissue. Smooth muscle cells in the theca externa contract under prostaglandin stimulation, generating the mechanical force that expels the oocyte-cumulus complex. The oocyte resumes meiosis I (completing it to form the secondary oocyte and first polar body) and arrests again at metaphase II, awaiting fertilisation to complete meiosis II.
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. Because prostaglandins — particularly PGE2 — are required for follicle rupture during ovulation, NSAIDs taken around the time of the LH surge can impair or prevent follicle rupture (lutenoised unruptured follicle syndrome), even though the LH surge and luteinisation proceed normally. This effect has been demonstrated with diclofenac, naproxen, and high-dose aspirin, and is reversible — the effect resolves with cessation of NSAID use. Clinically, this interaction is significant for women with dysmenorrhoea who take NSAIDs continuously around ovulation, for women taking NSAIDs for pain management during fertility investigations, and as a consideration in women with unexplained infertility who are regular NSAID users. Paracetamol (acetaminophen) does not significantly inhibit peripheral COX-2 and does not impair ovulation.
For students encountering this topic in pharmacology, obstetrics, or nursing examinations, our nursing assignment help and custom science writing services provide expert coverage of drug-hormone interactions in reproductive physiology.
The Corpus Luteum — Progesterone Factory and Early Pregnancy Sustainer
The corpus luteum (Latin: yellow body — named for its characteristic colour from lutein pigment and lipid droplets) is one of the most metabolically active transient endocrine structures in the body. It forms from the collapsed follicle within hours of ovulation, reaches full secretory capacity within 5–7 days, and is maintained or regressed depending entirely on whether hCG from an implanting embryo reaches it within its natural 12–14 day lifespan.
Corpus Luteum Formation and Progesterone Synthesis
After follicle rupture, the granulosa and theca cells left behind undergo dramatic morphological transformation — granulosa lutein cells (the primary progesterone producers) hypertrophy and accumulate lipid droplets; theca lutein cells continue androgen production. New blood vessels rapidly penetrate the previously avascular granulosa cell layer — a critical angiogenic step that supplies the cholesterol substrate for steroidogenesis via LDL-derived cholesterol uptake. LH — binding LH receptors on luteal cells — drives StAR-mediated cholesterol transport into the mitochondrial inner membrane, where CYP11A1 (P450scc) initiates the steroidogenic cascade: cholesterol → pregnenolone → progesterone.
Progesterone production peaks at the mid-luteal phase (day 21–22 of a 28-day cycle), reaching 16–95 nmol/L. This mid-luteal progesterone peak is the clinically sampled endpoint used to confirm ovulation: a day 21 serum progesterone >30 nmol/L (or >16 nmol/L in some laboratory thresholds) confirms that ovulation and normal luteal function occurred. A sub-optimal mid-luteal progesterone — despite apparent ovulation — suggests luteal phase deficiency (LPD), which is associated with implantation failure and recurrent miscarriage, and which may be treated with progesterone supplementation in the luteal phase.
The corpus luteum also continues oestradiol production (from theca-derived androgens, aromatised by luteal granulosa cells) and produces inhibin A — explaining the mid-luteal oestradiol secondary peak and the inhibin A peak that suppresses FSH during the luteal phase, preventing premature next-cycle follicle recruitment.
For students studying reproductive physiology, gynaecology, or obstetrics, our nursing assignment help and public health assignment help cover corpus luteum function, luteal phase assessment, and progesterone supplementation in depth across all academic levels.
Hormones of Pregnancy — hCG, Placental Oestrogen, Progesterone, and Beyond
Pregnancy transforms the female endocrine system fundamentally. The placenta — a transient organ of foetal origin — becomes the dominant endocrine organ from the late first trimester, producing oestrogen, progesterone, hCG, human placental lactogen (hPL), and a range of growth factors that override and redirect the normal hypothalamic-pituitary-ovarian axis for the duration of gestation.
Human Chorionic Gonadotrophin — The Pregnancy Signal
hCG is the glycoprotein hormone of pregnancy, produced by syncytiotrophoblast cells from the moment of implantation. Its beta subunit is unique to hCG (distinguishing it from LH in immunoassays — the basis of pregnancy tests detecting beta-hCG), while its alpha subunit is shared with FSH, LH, and TSH. hCG rises exponentially in early pregnancy, doubling approximately every 48–72 hours in normal intrauterine pregnancy, peaking at weeks 10–12 (reaching 100,000–200,000 IU/L), then declining to a plateau of 20,000–50,000 IU/L for the remainder of pregnancy. Its primary role is corpus luteum rescue — maintaining progesterone production until the placenta assumes steroidogenesis at weeks 8–10. hCG also has mild TSH-like activity (sharing alpha subunit and structural homology), causing a slight hyperthyroid state in early pregnancy (gestational transient thyrotoxicosis) and suppressing TSH in the first trimester — relevant to thyroid function test interpretation in pregnancy.
The Dominant Second and Third Trimester Progestogen
From approximately week 10, the placenta progressively assumes the dominant role in progesterone production — taking over from the corpus luteum in the “luteal-placental shift.” Placental progesterone is synthesised from maternal LDL-derived cholesterol (the placenta lacks de novo cholesterol synthesis capacity), with the syncytiotrophoblast converting cholesterol to pregnenolone and then progesterone via CYP11A1 and 3-beta-HSD. Unlike corpus luteum progesterone, placental progesterone production is not LH/hCG-dependent — the placenta has its own autonomous steroidogenic capacity. By the third trimester, plasma progesterone reaches 300–700 nmol/L — far exceeding luteal phase levels — maintained to suppress myometrial contractility until parturition is initiated through a functional progesterone withdrawal (PR-A/PR-B isoform ratio shift, rather than declining circulating levels).
Oestriol from the Fetoplacental Unit
Placental oestrogen synthesis uses the foetus as a steroidogenic partner — the placenta cannot synthesise androgens de novo (lacking CYP17A1), so it relies on the foetal adrenal gland and liver as androgen precursor suppliers. The foetal adrenal produces DHEAS (dehydroepiandrosterone sulphate), which the placenta desulphates and aromatises to oestrone and oestradiol; foetal liver 16-hydroxylation of DHEAS produces 16-OH-DHEAS, which the placenta converts to oestriol (E3). This two-organ, two-species (mother-foetus) synthesis pathway explains why oestriol is unique to pregnancy and why unconjugated oestriol in maternal serum reflects foetal adrenal and hepatic function — low oestriol indicating foetal compromise (Down syndrome, placental sulphatase deficiency, foetal anaemia) and high oestriol indicating multiple pregnancy.
Human Placental Lactogen and Relaxin
Human placental lactogen (hPL, also called human chorionic somatomammotrophin) is a protein hormone with structural homology to growth hormone and prolactin. It antagonises insulin action in maternal tissues, diverting glucose to the foetus — a primary driver of gestational diabetes mellitus in susceptible women. hPL also stimulates maternal lipolysis (providing free fatty acids as maternal metabolic substrate, sparing glucose for foetal use) and contributes to mammary gland development. Relaxin, produced by the corpus luteum and placenta, remodels the cervical connective tissue (cervical ripening), loosens pelvic ligaments in preparation for delivery, and promotes uterine growth. Placental CRH rises exponentially in the third trimester, contributing to the late pregnancy hormonal changes that trigger labour through cortisol and prostaglandin pathways.
Prolactin and Oxytocin — The Hormones of Lactation and Parturition
Prolactin and oxytocin are produced in the pituitary gland (anterior and posterior pituitary respectively) and serve distinct but complementary roles in the final stages of reproduction — birth and lactation — while also influencing behaviour, bonding, and immune function in ways that extend well beyond their classical endocrine roles.
Prolactin — Milk Production and Lactational Amenorrhoea
Prolactin is a 199-amino-acid protein hormone secreted by lactotroph cells of the anterior pituitary under tonic inhibitory control by dopamine — released from the tuberoinfundibular dopamine neurons into the portal vasculature to suppress prolactin secretion. Disruption of this dopamine inhibition (by dopamine antagonist drugs: antipsychotics, metoclopramide, domperidone; or by a prolactinoma compressing the pituitary stalk) causes hyperprolactinaemia — elevated prolactin that suppresses GnRH pulsatility, causing anovulation and amenorrhoea. During pregnancy, oestrogen stimulates lactotroph proliferation (pituitary doubles in size during pregnancy) and prolactin rises progressively, but lactation is inhibited by the high oestrogen and progesterone of pregnancy despite elevated prolactin. At delivery, the fall in placental oestrogen and progesterone unmasks prolactin action on alveolar mammary cells, initiating milk production (galactopoiesis). Suckling maintains elevated prolactin through the neuroendocrine suckling reflex (nipple stimulation → spinal cord → hypothalamus → inhibit dopamine release → prolactin rises), while simultaneously suppressing GnRH pulsatility — the mechanism of lactational amenorrhoea (contraceptive efficacy: approximately 98% in the first 6 months of exclusive breastfeeding, falling as feed frequency decreases).
Oxytocin — Uterine Contractions and Milk Ejection
Oxytocin is a nonapeptide (nine amino acids) synthesised in magnocellular neurons of the paraventricular and supraoptic nuclei of the hypothalamus and stored in the posterior pituitary (neurohypophysis) for release into the systemic circulation. Its two classical peripheral roles are uterine contraction (stimulating myometrial smooth muscle oxytocin receptors, which increase dramatically in density near term through oestrogen upregulation) and milk ejection (stimulating myoepithelial cells surrounding mammary gland alveoli to contract and expel milk into the ductal system — the let-down reflex). Synthetic oxytocin (Syntocinon) is the most widely used uterotonic in obstetrics — for labour induction and augmentation, and for prevention and treatment of post-partum haemorrhage by stimulating sustained uterine contraction after delivery. Oxytocin acts on a Gq-coupled GPCR → phospholipase C → IP3 → intracellular calcium → myosin light chain kinase activation pathway. Beyond its peripheral roles, oxytocin acts centrally as a neuropeptide modulating social bonding, trust, stress response, and pair bonding behaviour — properties that have generated significant research interest but equally significant overinterpretation in popular science media.
The Hormonal Changes of Menopause and the Perimenopause Transition
Menopause — defined as 12 consecutive months without menstruation in the absence of other pathological or physiological cause — results from the progressive depletion of the ovarian follicle pool below the threshold needed to sustain adequate oestrogen production and regular ovulation. The average age of menopause in women globally is approximately 51 years, with a normal range of 45–55 years. Menopause before age 40 is classified as premature ovarian insufficiency (POI) and before age 45 as early menopause.
Hormonal changes across the menopausal transition — directional shift relative to reproductive baseline
Vasomotor Symptoms — The Hypothalamic Thermostat Disrupted
Hot flushes and night sweats — experienced by approximately 75% of women during the menopausal transition — result from oestrogen withdrawal destabilising the hypothalamic thermoregulatory centre. Oestrogen normally narrows the thermoneutral zone — the temperature range within which sweating and vasodilation are not triggered. Oestrogen withdrawal widens temperature sensitivity, so small core temperature changes trigger exaggerated vasodilation, sweating, and the subjective sensation of heat. Kisspeptin/neurokinin B (NKB)/dynorphin neurons — the same cells that regulate GnRH pulsatility — are also involved in thermoregulation; NKB acting on NK3 receptors in the dorsomedial hypothalamus triggers the vasomotor response. The NK3 receptor antagonist fezolinetant (approved by the FDA and EMA in 2023) reduces hot flush frequency and severity through this mechanism — the first non-hormonal treatment targeting the central thermoregulatory mechanism rather than simply blunting peripheral symptoms.
Oestrogen Withdrawal and Bone Loss — Accelerated Post-Menopausal Osteoporosis
Bone density declines at approximately 1–2% per year in the first 5–10 years after menopause — a rate 3–4 times higher than the gradual pre-menopausal decline — driven by the loss of oestrogen’s inhibitory effect on osteoclast activity. ERα-mediated signalling in osteoblasts normally suppresses RANKL (receptor activator of nuclear factor kappa-B ligand) expression — the principal osteoclast-activating cytokine. Without oestrogen, osteoblasts produce more RANKL, osteoclast activity increases, and bone resorption exceeds formation. HRT (using oestrogen alone or combined with progestogen) prevents post-menopausal bone loss and is approved for osteoporosis prevention in women who are also symptomatic — making it the treatment of choice when symptom relief and bone protection are simultaneously needed.
Genitourinary Syndrome of Menopause — Urogenital Oestrogen Withdrawal
The genitourinary syndrome of menopause (GSM) encompasses vulvovaginal atrophy (thinning, loss of rugae, decreased lubrication), dyspareunia, recurrent urinary tract infections, urinary urgency, and urinary incontinence — all consequences of oestrogen receptor-mediated effects in the lower urogenital tract (vaginal epithelium, urethra, bladder base, pelvic floor). Unlike vasomotor symptoms, which often improve spontaneously over time, GSM is progressive without treatment. Local (vaginal) oestrogen therapy — available as cream, pessary, tablet, or ring — restores vaginal epithelial maturation, normalises pH, and relieves symptoms without clinically significant systemic absorption, making it appropriate even for women with contraindications to systemic HRT (e.g., hormone receptor-positive breast cancer survivors — though this remains a nuanced clinical discussion).
Androgens in Female Reproductive Physiology — Not Just Male Hormones
Androgens — testosterone, androstenedione, dihydrotestosterone (DHT), and DHEAS — are present in the female circulation at concentrations approximately 10% of male levels but are physiologically essential for normal female reproductive function, bone health, libido, and general wellbeing. They are produced by the ovaries (theca cells), the adrenal cortex (zona reticularis), and peripheral tissues (through local steroidogenesis and interconversion), and serve as obligatory precursors for oestrogen synthesis via aromatisation.
The clinical measurement of androgens in women is complicated by the low concentrations involved (requiring sensitive assays), diurnal variation (testosterone peaks in the morning), and the importance of free versus total testosterone (sex hormone-binding globulin — SHBG — binds testosterone avidly, and high SHBG in women on oral oestrogen-containing contraceptives reduces free testosterone). Calculating free androgen index (FAI = total testosterone/SHBG × 100) or measuring free testosterone directly provides a more clinically meaningful indicator of bioavailable androgen than total testosterone alone.
Clinical Applications — Contraception, Assisted Reproduction, and HRT
The hormones governing female reproduction are among the most extensively pharmacologically manipulated systems in medicine. Contraception, fertility treatment, and hormone replacement for menopause each exploits specific points in the HPG axis with precision-engineered steroid and peptide hormone analogues. Understanding the pharmacological basis of these interventions requires understanding the endogenous hormone system they replicate, suppress, or augment.
Reproductive Endocrinology in Examinations — Applied Clinical Reasoning
Female reproductive endocrinology is among the most heavily examined topics in nursing pharmacology, obstetrics and gynaecology, reproductive medicine, and human physiology assessments. Examination questions consistently test applied hormonal reasoning — identifying which hormone is deficient from a clinical vignette, explaining the mechanism by which a contraceptive method works, interpreting FSH/LH/oestradiol results in the context of cycle timing or fertility investigation, and predicting the hormonal consequences of pituitary or ovarian pathology. Students who learn the HPG axis as a connected system — rather than as isolated hormone facts — consistently outperform those who memorise reference ranges without understanding the feedback architecture that generates them.
Our nursing assignment help, biology assignment help, and nursing case study writing services provide expert support for reproductive endocrinology content at all levels — from foundational menstrual cycle essays through advanced clinical pharmacology assignments on hormonal contraception, ART protocols, and HRT prescribing frameworks.
Hormonal Disorders of Female Reproduction — When the HPG Axis Fails
The precision of the HPG axis makes it vulnerable to disruption at multiple levels. Hormonal disorders of female reproduction range from hypothalamic dysfunction (functional hypothalamic amenorrhoea) through pituitary pathology (hyperprolactinaemia, hypopituitarism) to primary ovarian disorders (PCOS, premature ovarian insufficiency) and uterine hormone-response abnormalities (endometrial receptor dysfunction, Asherman syndrome). Each disorder has a distinct hormonal fingerprint that enables diagnosis and directs targeted treatment.
Functional Hypothalamic Amenorrhoea (FHA)
FHA occurs when GnRH pulse frequency and amplitude are suppressed below the threshold required to maintain normal HPG axis function — typically caused by energy deficiency (eating disorders, excessive exercise, chronic illness), psychosocial stress, or weight loss. Low GnRH → low FSH and LH → low oestradiol → amenorrhoea. Hormonal profile: low FSH, low LH, very low oestradiol, low-normal AMH, negative progesterone challenge. Treatment is directed at the underlying cause (weight restoration, stress reduction, injury rehabilitation); pulsatile GnRH infusion can restore ovulatory cycles when the underlying cause cannot be immediately resolved and fertility is needed.
Hyperprolactinaemia
Elevated prolactin — from prolactinoma (microadenoma or macroadenoma), dopamine antagonist drugs, hypothyroidism (TRH stimulates prolactin), or stalk compression — suppresses GnRH pulsatility, causing anovulation, oligomenorrhoea, or amenorrhoea, often with galactorrhoea (spontaneous milk production). Hormonal profile: elevated prolactin (>500 mIU/L suspicious, >1000 mIU/L typically pathological), low-normal FSH and LH, low oestradiol. Treatment: dopamine agonists (cabergoline first-line) normalise prolactin, restore GnRH pulsatility, and rapidly reduce prolactinoma size. Surgery reserved for drug-resistant or apoplectic cases.
Polycystic Ovary Syndrome (PCOS)
The most common endocrine disorder in reproductive-age women (affecting 8–13%), characterised by androgen excess, ovulatory dysfunction, and polycystic ovarian morphology on ultrasound (Rotterdam criteria: 2 of 3 features). Hormonal basis: insulin resistance → hyperinsulinaemia → excess LH-stimulated theca cell androgen production + reduced SHBG (increasing free testosterone) → impaired follicle maturation and anovulation. AMH is markedly elevated (reflecting large antral follicle pool); LH:FSH ratio often elevated. Treatment: lifestyle modification (insulin sensitisation); metformin; clomiphene or letrozole for ovulation induction; combined OCP for cycle regulation and anti-androgenic effects.
Premature Ovarian Insufficiency (POI)
POI is loss of normal ovarian function before age 40, affecting approximately 1% of women. Primary POI: accelerated follicle depletion (genetic — Turner syndrome, FMR1 premutation; autoimmune; iatrogenic — chemotherapy, radiation, ovarian surgery). Secondary POI: pituitary or hypothalamic disorders preventing adequate gonadotrophin stimulation. Hormonal profile: FSH >25 IU/L (>40 IU/L on two occasions 4–6 weeks apart) combined with oestradiol <100 pmol/L; low AMH; anovulation. Treatment: HRT until average age of natural menopause (51) for cardiovascular, bone, and cognitive protection — POI without HRT carries significant long-term health risks beyond the immediate menopausal symptoms.
Endometriosis and Progesterone Resistance
Endometriosis — growth of endometrial-like tissue outside the uterus — is an oestrogen-dependent, inflammation-driven condition in which ectopic lesions express aromatase (producing local oestrogen) and show abnormal progesterone receptor expression (PR-A dominant, progesterone resistance). These lesions respond to oestrogen by proliferating and secreting inflammatory mediators (PGE2, IL-6, TNF-alpha), but fail to respond to progesterone with the normal secretory transformation and regression. Treatment targets oestrogen suppression (GnRH agonists/antagonists, combined hormonal contraception, progestogens at anti-ovulatory doses) and local progesterone receptor sensitisation. The newly approved oral GnRH antagonists (elagolix, linzagolix) offer non-injection medical management.
Thyroid Hormones and Reproductive Function
Thyroid hormones interact with the female reproductive system at multiple levels. Hypothyroidism elevates TRH (stimulating prolactin) causing hyperprolactinaemia and anovulation; reduces SHBG (increasing free androgen exposure); impairs corpus luteum function; and in pregnancy causes miscarriage, preterm birth, and neurodevelopmental impairment in offspring. Hyperthyroidism elevates SHBG, reducing free testosterone and oestradiol, and causes oligomenorrhoea or amenorrhoea. Autoimmune thyroid disease is closely associated with premature ovarian insufficiency (shared autoimmune pathogenesis) and recurrent miscarriage. TSH measurement is a routine part of fertility workup for this reason — the recommended pre-conception TSH target is <2.5 mIU/L.
Reproductive Physiology, Nursing, and Health Sciences Academic Support
From HPG axis essays and menstrual cycle assignments through gynaecology case studies, midwifery portfolios, and reproductive endocrinology literature reviews — specialist academic writers at every degree level.
Measuring Female Reproductive Hormones — Clinical Interpretation
Reproductive hormone measurements are only meaningful in the context of where in the menstrual cycle the sample was taken, the clinical question being answered, and the reference ranges appropriate for the assay platform used. Interpreting a hormone result without this contextual information is a source of systematic diagnostic error — the most common being misinterpretation of a normally elevated mid-cycle LH as polycystic ovary syndrome, or a normally low follicular-phase progesterone as luteal phase deficiency.
The StatPearls review of the female reproductive system on NCBI Bookshelf provides peer-reviewed coverage of reproductive hormones and the menstrual cycle suitable for undergraduate through postgraduate study. For clinical reproductive endocrinology reference data and evidence-based guidance on hormonal investigations, the European Society of Human Reproduction and Embryology (ESHRE) clinical guidelines cover PCOS, POI, ovarian stimulation, and endometriosis hormonal management with full methodological transparency.
Frequently Asked Questions About the Female Reproductive Hormones
Further reading and support: nursing assignment help · biology assignment help · biology research papers · chemistry homework · public health help · research paper writing · literature reviews · dissertation support · custom science writing · data analysis · nursing case studies · personalised academic help · citation and referencing · challenging research topics · critical analysis papers